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A b s t r a c t
Background: Exercise oscillatory ventilation (EOV) is a common pattern of breathing in heart failure (HF) patients, and
indicates a poor prognosis.
Aim: To investigate the effects of adaptive servoventilation (ASV) on ventilatory response during exercise.
Methods: We studied 39 HF patients with left ventricular ejection fraction (LVEF) £ 45. Cardiorespiratory polygraphy,
cardiopulmonary exercise testing (CPET), echocardiography, and measurement of N-terminal pro-brain natriuretic peptide
(NT-proBNP) concentration were performed. Twenty patients with Cheyne-Stokes respiration and apnoea–hypopnoea in-
dex (AHI) ≥ 15/h were identified. Of these, 11 patients were successfully titrated on ASV and continued therapy. In the third
month of ASV treatment, polygraphy, CPET, echocardiography, and measurement of NT-proBNP concentration were per-
formed again.
Results: The EOV was detected at baseline in 12 (31%) HF patients, including eight (67%) who underwent ASV. The EOV was
associated with significantly lower LVEF, peak oxygen uptake (VO2), and ventilatory anaerobic threshold (VAT), and a signi-
ficantly higher left ventricular diastolic diameter (LVDD), slope of ventilatory equivalent for carbon dioxide (VE/VCO2), AHI,
central AHI and NT-proBNP concentration. In seven patients with EOV, reversal of EOV in the third month of ASV therapy
was observed; only in one patient did EOV persist (p = 0.0156).
Conclusions: The EOV can be reversed with ASV therapy. The EOV in association with central sleep apnoea and Cheyne-
-Stokes respiration (CSA/CSR) is prevalent in HF patients and correlates with severity of the disease.
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INTRODUCTION
Periodic breathing is a common ventilation pattern in heart
failure (HF) patients. It has been observed both during sleep
and exercise. The prevalence of central sleep apnoea asso-
ciated with Cheyne-Stokes respiration (CSA/CSR) and exerci-
se oscillatory ventilation (EOV) in HF patients has been re-
ported to range from 28% to 40%, and from 7% to 35%, re-
spectively [1–6]. Although EOV is present in only a minority
of patients with CSA/CSR, almost all EOV patients have CSA/
/CSR [4]. Both CSA/CSR and EOV have been identified as
strong predictors of mortality in HF patients, the latter being
the most powerful one of all cardiopulmonary exercise te-
sting-derived variables [4–9].
Adaptive servoventilation (ASV) is a novel effective the-
rapeutic method for reducing CSA. The ASV provides low
levels of background expiratory positive airway pressures to
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which a variable amount of inspiratory pressure support is
added. The amount of ventilatory support depends on the
actual breathing effort of the patient. It has been shown that
by correcting periodic breathing, ASV may improve sleep
quality and cardiovascular function [10–14]. Because CSA/
/CSR and EOV appear to have the same underlying patho-
physiologic mechanism [4, 15], it seems reasonable to expect
that correction of CSA/CSR may reverse EOV.
Therefore, the purpose of the present study was to investi-
gate the effects of ASV on periodic breathing during exercise.
METHODS
Study population and design
We prospectively studied patients with systolic HF due to
ischaemic or idiopathic dilated cardiomyopathy referred for
sleep study and cardiopulmonary exercise testing (CPET) as
part of comprehensive HF evaluation. Eligibility criteria were
as follows: (1) echocardiographic left ventricular ejection frac-
tion (LVEF) £ 45%; (2) New York Heart Association (NYHA)
class I–III; (3) clinical stability with optimal medical treatment
for at least one month; and (4) ability to perform CPET. Exc-
lusion criteria were: (1) acute coronary syndrome within the
last month; (2) patients with pacemakers, cardioverter-defi-
brillators or cardiac resynchronisation devices implanted wi-
thin the last six months; (3) severe chronic obstructive pul-
monary disease; and (4) history of stroke. All patients under-
went polygraphy, CPET, echocardiography and determina-
tion of N-terminal pro-brain natriuretic peptide (NT-proBNP)
concentration. The ASV therapy was offered to patients with
moderate to severe CSA/CSR — apnoea-hypopnoea index
(AHI) ≥ 15 and for whom there were no other conventional
therapeutic options. In the third month of ASV therapy, po-
lygraphy, CPET, echocardiography and measurement of
NT-proBNP concentration were performed again.
Cardiopulmonary exercise testing
Symptom-limited CPET was performed on a cycle ergometer
with a ramp protocol that was personalised with the aim of
having each patient reach maximum exercise in 7 to 10 min.
Breath-by-breath measurements of gas exchange were obta-
ined by a metabolic cart (ZAN 680, ZAN Messgerate GmbH,
Germany). Minute ventilation (VE), oxygen uptake and car-
bon dioxide output (VCO2) were averaged over 10 s. Peak
VO2 was expressed as the mean value of VO2 during the last
60 s of the exercise test. Ventilatory anaerobic threshold (VAT)
was detected by the V-slope method. The VE/VCO2 slope
was calculated as a linear regression function using the data
points from the whole exercise period. Peak oxygen pulse
(O2 pulse) was delineated as peak VO2 divided by peak heart
rate. The EOV was defined according to the following crite-
ria: (1) three or more regular oscillations in VE; (2) a regular
oscillation as defined by the standard deviation of three con-
secutive cycle lengths within 20% of the average; and (3) mi-
nimal average amplitude of ventilatory oscillation of 5 L [7].
Echocardiography
Standard M-mode and two-dimensional (2D) echocardiogra-
phy and Doppler blood flow measurements were performed
in all patients (Vivid 7 Dimension, GE Healthcare, USA). The
LVEF was calculated according to Simpson’s method from
a 2D apical view.
Sleep study
All patients underwent in-hospital unattended polygraphy
(Embletta™, Embla, The Netherlands) with recording of nasal
air flow, chest and abdominal movement, pulse oximetry and
body position. Analysis was performed automatically using
standard software (Somnologica for Embletta™, Embla, The
Netherlands) and subsequently reviewed and corrected by
a sleep-disordered breathing specialist. Apnoea and hypo-
pnoea were defined according to the American Academy of
Sleep Medicine criteria [16]. Apnoeic events were detected
when at least 10 s interval of the air flow signal dropped to
£ 10% of baseline. Hypopnoeic events were detected when
at least 10 s interval of the air flow signal dropped to £ 70%
of baseline in combination with a ≥ 4% oxygen desaturation.
Apnoea and hypopnoea were classified as either central or
obstructive, depending on the absence or presence of thorax
and abdominal movements. Cheyne-Stokes breathing was
scored when there were at least three consecutive cycles of
crescendo-decrescendo breathing amplitude with coexisting
one of the following: (1) central AHI ≥ 5; (2) the cyclic cre-
scendo-decrescendo change in breathing amplitude lasted
for at least ten consecutive minutes. The CSA/CSR was classi-
fied as severe when AHI was at least 30, and moderate when
the AHI was at least 15 and less than 30.
NT-proBNP
Blood samples were taken from all patients to determine
NT-proBNP concentration (cobas e411, Roche, Switzerland).
Adaptive servoventilation
Servo-ventilation devices provide a mode of pressure support
to treat obstructive and complex central sleep apnoea disor-
ders. Dynamic bilevel pressure (BPAP) provides positive air-
way pressure support to sustain upper-airway patency. The
expiratory pressure is set to eliminate obstructive apnoea/hy-
popnoea during sleep. The ASV device changes the inspiratory
pressure above the expiratory pressure as required to normali-
se patients’ ventilation. When the device detects normal bre-
athing, dynamic BPAP acts like fixed continuous positive air-
way pressure (CPAP) by providing minimal pressure support;
when the patient does not maintain the target peak inspiratory
airflow, the device increases the pressure support above the
expiratory pressure up to a maximum pressure, which can be
set by the user. The device also provides automatic, timed,
backup breaths during central apnoeas. The optimal backup
rate is automatically determined by the device (based on the
patient’s sleep-disordered breathing presentation).
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Therapeutic ASV was delivered from one of two devices
(BIPAP AutoSV Advanced, Philips Respironics, Murrysville,
PA, USA or AutoSet CS2, ResMed, Sydney, Australia) for three
months. The therapy was initiated using the default settings
and during the hospital stay was titrated with the aim of redu-
cing the AHI to £ 10.
The study was approved by the Institutional Review Bo-
ard of the Military Medical Chamber (IRB followed the Hel-
sinki recommendations, approval number 38/07). All subjects
provided informed consent.
Statistical analysis
Continuous data are expressed as mean ± SD or as median
and first and third quartile in the case of skewed distributions
(NT-proBNP). Characteristics of the study groups were com-
pared by an unpaired Student t test or Mann-Whitney U test
in case of non-normally distributed data. A Wilcoxon signed
rank test or sign test were used for repeated measures (because
of small sample size). For qualitative variables, the c2 test with
Yates’ correction and Fisher exact test, if necessary, was em-
ployed. Statistical differences with a p value < 0.05 were con-
sidered significant. All calculations were performed with stati-
stical software (SAS 9.2, SAS Institute Inc., Cary, NC, USA).
RESULTS
Between January 2007 and September 2010, 39 patients met
the inclusion criteria and were enrolled in this study. Demogra-
phic and clinical data for these patients are set out in Table 1.
Moderate to severe CSA/CSR was observed in 20 (51%)
of the study sample. Ten (26%) of these presented a severe
form (AHI ≥ 30) of sleep-disordered breathing. The EOV was
detected in 12 (31%) subjects. Of all EOV patients, ten (83%)
had AHI ≥ 15, while the other two (17%) patients had mild
CSA/CSR. Compared to patients without EOV, patients with
EOV had a significantly lower LVEF, peak VO2, and VAT, and
a significantly higher left ventricular diastolic diameter (LVDD),
VE/VCO2 slope, AHI, central AHI and NT-proBNP concen-
tration (Table 1). Moreover, patients with EOV were signifi-
cantly older and more frequently had permanent atrial fibril-
lation. There were no significant between-group differences in
relation to other demographic and clinical characteristics,
including NYHA functional class and O2 pulse (Table 1).
Table 1. Demographic and clinical data of the studied population
Variable Total population EOV patients No-EOV patients P*
(n = 39)  (n = 12)  (n = 27)
Age [years] 61 ± 10 67 ± 8 59 ± 10 0.01
Male gender 39 (100%) 12 (100%) 27 (100%)
Body mass index [kg/m2] 30.0 ± 4.9 28.4 ± 4.8 30.7 ± 4.9 0.19
NYHA class 2.4 ± 0.6 2.6 ± 0.5 2.3 ± 0.7 0.24
Ischaemic aetiology 26 (67%) 9 (75%) 17 (63%) 0.71
Atrial fibrillation 8 (21%) 6 (50%) 2 (7%) 0.006
LVEF [%] 31 ± 7 28 ±6 33 ± 7 0.04
LVDD [cm] 6.6 ± 0.7 7.0 ±0.7 6.4 ± 0.6 0.02
Peak VO2 [mL/kg/min] 13.8 ± 4.2 11.4 ±1.9 14.9 ± 4.4 0.001
VAT [mL/kg/min] 10.7 ± 2.9 9.5 ±1.4 11.1 ± 3.3 0.047
O2 pulse [mL/beat/kg/100] 13.4 ± 3.4 12.0 ±3.3 14.0 ± 3.4 0.10
VE/VCO2 slope 34.2 ± 8.6 41.1 ±7.3 31.2 ± 7.4 0.002
NT-proBNP [pg/mL] 839 (315; 3,101) 3,164 (855; 4,722) 375 (228; 1,143) 0.002
AHI [h–1] 22.0 ± 16.6 31.1 ± 15.3 17.9 ± 15.7 0.01
AHI central [h–1] 16.3 ± 16.1 28.2 ± 15.8 11.1 ± 13.4 0.004
Medications:
ACE-I or ARB 38 (97%) 12 (100%) 26 (96%) 1.00
Beta-blockers 38 (97%) 12 (100%) 26 (96%) 1.00
Diuretics 36 (92%) 12 (100%) 18 (86%) 0.54
Spironolactone 32 (82%) 11 (92%) 21 (78%) 0.40
*EOV patients vs no-EOV patients; EOV — exercise oscillatory ventilation; NYHA — New York Heart Association; LVEF — left ventricular ejection fraction;
LVDD — left ventricle diastolic diameter; VAT — ventilatory anaerobic threshold; VE/VCO2 slope — slope of ventilatory equivalent for carbon dioxide;
NT-proBNP — N-terminal pro-brain natriuretic peptide; AHI — apnoea-hypopnoea index; ACE-I — angiotensin-converting enzyme inhibitors;
ARB — angiotensin-II receptor blocker
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Of 20 patients with moderate to severe CSA/CSR, 14 pa-
tients were offered ASV therapy (the remaining six patients
had other conventional therapeutic options such as  cardio-
verter-defibrillator or cardiac resynchronisation device implan-
tation). Two patients declined ASV therapy because of mask
intolerance, and one subject for no specific reason. A total of
11 patients were successfully titrated on ASV, continued ASV
therapy and underwent a follow-up visit in the third month
of therapy. Medical treatment remained unchanged throu-
ghout the whole study period.
Resolution of exercise oscillatory ventilation
Eight patients out of 11 treated with ASV had EOV before
therapy. The EOV was reversed in seven (86%) patients, and
only in one patient did EOV persist (p = 0.0156). An exam-
ple of the EOV pattern and its resolution is shown in Figure 1.
Sleep study
The AHI normalised during therapy, and resolution of Cheyne-
-Stokes breathing pattern was observed in all patients. There
was a trend towards an improvement in mean nocturnal oxy-
gen saturation, minimum nocturnal oxygen saturation and
mean oxygen desaturation, but these did not reach statistical
significance (Table 2).
Exercise response
Oxygen pulse increased significantly. There were trends to-
wards an increase in peak oxygen uptake and VAT, but these
did not reach statistical significance. The VE/VCO2 slope did
not change significantly (Table 2).
History, echocardiography and NT-proBNP
The LVEF increased significantly. The LVDD remained unchan-
ged. There was a significant fall in the NT-proBNP concentration.
There was a trend towards an improvement in NYHA functional
class, but this did not reach statistical significance (Table 2).
DISCUSSION
Although periodic breathing during exercise in HF patients was
described for the first time over 20 years ago [17], its clinical
significance has only recently been appreciated. Recent reports
have shown that EOV holds a high prognostic value in HF risk
stratification. The EOV is superior to other conventional CPET-
-derived variables, including peak VO2 and VE/VCO2 slope, in
predicting mortality and major cardiac events [4–9].
In this prospective study, we have demonstrated resolu-
tion of EOV with ASV therapy. Indeed, in all patients except
for one treated with ASV, abnormal ventilatory pattern at ba-
seline reversed in the third month of therapy.
The ASV is a novel method of treating patients with CSA/
/CSR. In our study, the effects of reverting EOV with ASV were
accompanied by effective suppression of sleep-disordered
breathing. The mechanisms responsible for resolution of EOV
with ASV therapy are now a matter of speculation. It seems
that periodic breathing both during sleep and exercise are
coupled by the same pathophysiological mechanism [4, 15].
Both EOV and CSA/CSR are strictly associated with severity
of HF. It has been demonstrated that different methods of
therapy improving cardiac function, including medical treat-
ment [18], cardiac surgery [19] and cardiac resynchronisation
[20], may resolve sleep-disordered breathing. Only one stu-
dy has reported reversal of abnormal ventilatory pattern du-
ring exercise in three patients treated with milrinone and two
patients who underwent heart transplantation [17].
We observed EOV in 31% of patients and all patients
with EOV had CSA/CSR. Our findings are similar to previo-
usly published data reporting the prevalence of EOV in HF
patients of between 7% and 35%, and the coexistence of
nocturnal with exertional periodic breathing [4–6]. Our re-
sults also confirmed a previously found correlation between
EOV and severity of HF and impaired functional capacity [4–
–9, 21]. In the current study, patients with EOV compared to
those without EOV had significantly lower LVEF, peak VO2,
Figure 1. Representative example of exercise oscillatory ventilation (EOV) at baseline (A), and its resolution in the third month of
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and VAT, and significantly higher LVDD, VE/VCO2 slope, AHI,
central AHI and NT-proBNP concentration.
The ASV therapy not only reversed EOV and CSR, but
also improved LVEF and decreased NT-proBNP concentra-
tion, which is in line with the findings of previous studies [10].
On the other hand, there was no significant improvement in
NYHA functional class — which is probably a consequence
of the short-term follow-up and small study group. Our re-
sults support the observation that ASV therapy does not chan-
ge VE/VCO2 slope [10].
Limitations of the study
The study was uncontrolled, the sample size was small, and
the follow-up was short. The study showed that EOV could
be reversed with ASV therapy, but the effects of EOV resolu-
tion on prognosis are unknown. Further studies are required
to address this issue.
CONCLUSIONS
The present study provides original observation that periodic
breathing during exercise could be reversed with ASV therapy.
Because of the limitations of the study, further data is required.
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Ustąpienie periodycznego oddychania
w czasie wysiłku u pacjentów z przewlekłą
niewydolnością serca i oddychaniem
typu Cheyne−Stokesa leczonych
adaptoserwowentylacją: doniesienie wstępne
Anna Kazimierczak, Krystian Krzyżanowski, Robert Wierzbowski, Robert Ryczek,
Paweł Smurzyński, Dariusz Michałkiewicz, Zbigniew Orski, Grzegorz Gielerak
Klinika Kardiologii i Chorób Wewnętrznych, Wojskowy Instytut Medyczny, Warszawa
S t r e s z c z e n i e
Wstęp: Periodyczne oddychanie jest częstym zjawiskiem u pacjentów z przewlekłą niewydolnością serca (HF). Występuje
ono nie tylko w czasie snu, ale i podczas wysiłku. Periodyczne oddychanie w czasie wysiłku (EOV) jest silnym predykatorem
śmiertelności z przyczyn sercowych u pacjentów z HF. Adaptoserwowentylacja (ASV) jest nową metodą leczenia osób
z oddychaniem typu Cheyne-Stokesa. Wykazano, że znacznie redukuje ona centralne bezdechy senne i normalizuje patolo-
giczny tor oddychania w czasie snu.
Cel: Celem badania była ocena wpływu ASV na tor oddychania w czasie wysiłku.
Metody: Do badania włączono 39 pacjentów z przewlekłą HF, z frakcją wyrzutową lewej komory (LVEF) £ 45%. U wszyst-
kich chorych wykonano badanie poligraficzne, ergospirometryczną próbę wysiłkową, badanie echokardiograficzne i ozna-
czono stężenie N-końcowego propeptydu natriuretycznego typu B (NT-proBNP). Oddychanie typu Cheyne-Stokesa i wskaź-
nik AHI (apnea–hypopnea) > 15/h stwierdzono u 20 (51%) pacjentów. U 11 spośród nich skutecznie wdrożono leczenie
ASV. W 3. miesiącu terapii ponownie wykonano badanie poligraficzne, ergospirometryczną próbę wysiłkową, badanie echo-
kardiograficzne i oznaczono stężenie NT-proBNP.
Wyniki: U 12 (31%) pacjentów z HF stwierdzono EOV, w tym u 8 (67%) leczonych ASV. Chorzy z EOV w porównaniu
z osobami z prawidłowym torem oddychania w czasie wysiłku charakteryzowali się istotnie niższą LVEF, szczytowym pochła-
nianiem tlenu (VO2), progiem beztlenowym oraz istotnie większym rozkurczowym wymiarem lewej komory, nachyleniem
VE/VCO2, AHI, centralnym AHI i stężeniem NT-proBNP. W 3. miesiącu terapii ASV stwierdzono ustąpienie EOV u 7 pacjen-
tów, tylko u 1 osoby nie zaobserwowano poprawy w zakresie toru oddychania (p = 0,0156). Wśród pozostałych parametrów
ergospirometrycznych tylko puls tlenowy istotnie wzrósł. Szczytowe pochłanianie tlenu i próg beztlenowy nieznacznie się
poprawiły, ale różnice te nie osiągnęły istotności statystycznej. U wszystkich pacjentów leczonych ASV stwierdzono norma-
lizację toru oddychania w czasie snu i zmniejszenie AHI do < 5/h. Ponadto w trakcie leczenia ASV zaobserwowano zna-
mienne zwiększenie LVEF i istotną redukcję stężenia NT-proBNP.
Wnioski: Badanie pokazuje oryginalne zjawisko normalizacji toru oddychania w czasie wysiłku u pacjentów z centralnym
bezdechem sennym leczonych ASV. Na podstawie powyższych danych nie można jednak wnioskować bezpośrednio
o znaczeniu klinicznym tej obserwacji. Wpływ ustąpienia EOV w czasie leczenia ASV na rokowanie odległe wymaga przepro-
wadzenia dalszych badań. Również ze względu na ograniczenia tego badania (krótki okres obserwacji, mała grupa badana) jego
wyniki wymagają potwierdzenia w kolejnych pracach.
Słowa kluczowe: oddychanie periodyczne w czasie wysiłku, zaburzenia oddychania w czasie snu
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